XML 112 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting  
Schedule of segment significant expense categories

The table below is a summary of the segment loss, including significant segment expenses (in thousands):

    

Year Ended December 31, 

2024

2023

Grant income

$

19,549

$

24,805

Less:

 

 

Clinical programs

27,675

21,180

R&D Personnel costs(1)

9,672

8,523

Preclinical programs

810

3,503

Manufacturing

2,241

2,890

Other research and development expenses

198

430

General and administrative expenses(2)

9,622

9,844

Equity-based compensation

3,748

4,354

Other segment items(3)

 

(446)

 

(131)

Segment and consolidated net loss

$

(33,971)

$

(25,788)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.